8.485

13.51% -1.325

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $8.485, with a volume of 1.99M. It is down -13.51% in the last 24 hours and up +10.77% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$9.81

Open:

$9.88

24h Volume:

1.99M

Relative Volume:

1.79

Market Cap:

$515.85M

Revenue:

Net Income/Loss:

$-156.40M

P/E Ratio:

-2.587

EPS:

-3.2799

Net Cash Flow:

$-151.53M

1W Performance:

-4.56%

1M Performance:

+10.77%

6M Performance:

+1.98%

1Y Performance:

+137.68%

1-Day Range:

$8.31

$9.90

1-Week Range:

$8.31

$10.29

52-Week Range:

$2.80

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX Kyverna Therapeutics Inc	8.485	515.85M	0	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-24	Initiated	UBS	Buy
Oct-09-24	Initiated	Rodman & Renshaw	Buy
Jul-03-24	Initiated	H.C. Wainwright	Neutral
Mar-04-24	Initiated	JP Morgan	Overweight
Mar-04-24	Initiated	Leerink Partners	Outperform
Mar-04-24	Initiated	Morgan Stanley	Overweight
Mar-04-24	Initiated	Wells Fargo	Overweight

View All

Kyverna Therapeutics Inc Stock (KYTX) Latest News

Jul 10, 2026

Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.

Jul 10, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1%Time to Sell? - MarketBeat

Jul 10, 2026

Jul 09, 2026

Enterprise value to EBIT forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView

Jul 09, 2026

Price to sales forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView

Jul 09, 2026

Price to book forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView

Jul 09, 2026

Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary - Quartr

Jul 09, 2026

Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond - Insider Monkey

Jul 09, 2026

Kyverna Therapeutics, Inc. Files 8-K: Key Details on Nasdaq Listing, Emerging Growth Status, and Executive Signatures - Minichart

Jul 09, 2026

Kyverna Therapeutics Amends Term Loan, Extends Capital Access - TipRanks

Jul 09, 2026

Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches - Stock Titan

Jul 09, 2026